Austin, May 22, 2025 (GLOBE NEWSWIRE) -- According to SNS Insider, The Pulmonary Arterial Hypertension Market size was valued at USD 7.91 billion in 2024 and is expected to grow to USD 12.18 billion by 2032, at a CAGR of 5.60% during the 2025–2032 forecast period. Rare and fatal, pulmonary arterial hypertension nonetheless inspires pharmaceutical innovation, particularly with government backing for orphan drug development, better diagnostics, and targeted therapies.
Early diagnosis, availability of sophisticated medicines, and robust clinical research infrastructure are mostly driving the significant expansion in the PAH industry observed in the United States. With a CAGR of 5.36%, the U.S. Pulmonary Arterial Hypertension Market is expected to rise to USD 3.95 billion by 2032 from USD 2.61 billion in 2024. Supported by FDA approvals for PAH-targeted therapies, the existence of important pharmaceutical actors, and major public health funding toward rare illness research.
Get a Sample Report of Pulmonary Arterial Hypertension Market@ https://www.snsinsider.com/sample-request/6950
Major Players Analysis Listed in this Report are:
- Johnson & Johnson
- United Therapeutics Corporation
- Bayer AG
- Gilead Sciences, Inc.
- Merck & Co., Inc.
- Novartis AG
- AbbVie Inc., Acceleron Pharma, Inc.
- Arena Pharmaceuticals, Inc.
- Sandoz and other players.
Pulmonary Arterial Hypertension Market Report Scope
| Report Attributes | Details |
| Market Size in 2024 | US$ 7.91 billion |
| Market Size by 2032 | US$ 12.18 billion |
| CAGR | CAGR of 5.60% From 2025 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Key Regional Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America) |
Segment Analysis
By drug class
Leading drug class in the PAH sector, prostacyclin and prostacyclin analogues accounted for 48.10% of the global market share in 2024. Crucially, in controlling severe instances, these drugs dilate pulmonary arteries and reduce platelet aggregation. Among common medications in this group are Iloprost, Treprostinil, and Epoprostenol. Though clinically beneficial, they may need constant infusion, which can be difficult for patients. On the other hand, the development of oral and inhalable formulations recently has increased patient compliance and expanded the attractiveness of this therapeutic class. Anticipated to further increase the dominance of this market is the significant investments pharmaceutical companies are making in developing next-generation prostacyclin medicines with longer half-lives and more flexible dosing schedules.
By Type
Branded medications accounted for 68.12% of the global PAH market in 2024. Strong patent portfolios and excellent efficacy of branded treatments as Opsumit, Adempas, Letairis, and Tracleer, help to explain this dominance. Supported by thorough clinical studies, the ongoing physician inclination for these reliable drugs guarantees constant demand. Moreover, new branded drugs under development gain from orphan drug classification and market exclusiveness, therefore postponing the arrival of generics. Personalized medicine tactics and fixed-dose combinations are also becoming more popular in the pharmaceutical scene, which encourages the use of branded drugs even more than generic ones. Still, the trend toward generic adoption may increase when many important patents expire by the end of the decade; branded pharmaceuticals are predicted to lead the market over the forecast period.
By Route of Administration
With 52.11% of the PAH market share, the oral segment dominated the PAH market in 2024. Compared to intravenous or subcutaneous therapies, oral drugs are chosen for their simplicity of use, improved patient compliance, and economy of expense. Especially recommended for people in early to moderate illness stages are phosphodiesterase-5 inhibitors (PDE5i) and oral endothelin receptor antagonists (ERAs). New developments such as combo treatments and extended-release tablets are broadening the segment even more. This segment is expected to keep its dominance through 2032 as businesses keep enhancing the bioavailability and tolerance of oral medicines, especially for long-term PAH control.
Buy a Single-User PDF of Pulmonary Arterial Hypertension Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/6950
Pulmonary Arterial Hypertension Market Segmentation
By Drug Class
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
By Type
- Branded
- Generics
By Route of Administration
- Oral
- Intravenous/ subcutaneous
- Inhalational
Regional analysis
With a 38.21% share in 2024, North America led the global pulmonary arterial hypertension market. Strong presence of big pharmaceutical players, extensive healthcare infrastructure, and solid reimbursement rules help the area thrive. Accelerating drug approvals and supporting clinical studies, the U.S. National Institutes of Health (NIH) and the FDA have greatly helped rare disease treatment development. Furthermore, supporting market growth is the growing senior population of the area, more vulnerable to pulmonary disorders.
Driven by rising patient awareness, government funding for rare diseases, and improvements in diagnostic imaging, Europe boasts a sizable market share. Additionally, pushing rapid approval schemes for PAH treatments is the European Medicines Agency (EMA).
larger urban pollution, a larger patient pool, and increasing access to healthcare in nations such as China and India would likely cause the Asia-Pacific region is grow with the fastest CAGR throughout the projection period. In low-income nations, however, poor knowledge and expensive treatment expenses still present difficulties.
Need Any Customization Research on Pulmonary Arterial Hypertension Market, Enquire Now@ https://www.snsinsider.com/enquiry/6950
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2024)
5.2 Drug Utilization and Prescription Patterns (2024), by Region
5.3 Treatment Adoption Rate and Patient Compliance (2020–2032)
5.4 Healthcare Expenditure on PAH Management (2024), by Region and Payer Type
6. Competitive Landscape
7. Pulmonary Arterial Hypertension Market by Drug Class
8. Pulmonary Arterial Hypertension Market by Type
9. Pulmonary Arterial Hypertension Market by Route of Administration
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion
Related Reports
Aerosol Drug Delivery Devices Market to Soar to $80.43 Billion by 2032 at 13.19% CAGR
Heparin Market to Hit $9.61 Billion by 2031 with 2.8% CAGR Growth
Respiratory Care Devices Market Set to Reach $43.35 Billion by 2032, Growing at 7.7% CAGR
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
